Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective: Review evidence to guide management of menopausal signs and symptoms in women after breast cancer and make recommendations accordingly. Evidence: Randomized controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies. Background: Symptoms and clinical problems associated with estrogen depletion-sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis-confront the estimated 9.3 million breast cancer survivors globally. Recommendations: Following breast cancer, women should not generally be treated with menopausal hormone therapy or tibolone but should optimize lifestyle. Women with moderate to severe symptoms may benefit from mind-brain behavior or nonhormone, pharmacologic therapy. The selective serotonin/noradrenaline reuptake inhibitors and gabapentenoid agents improve VMS and quality of life. For osteoporosis, nonhormonal agents are available. Treatment of VVA remains an area of unmet need. Low-dose vaginal estrogen is absorbed in small amounts with blood levels remaining within the normal postmenopausal range but could potentially stimulate occult breast cancer cells, and although poorly studied, is not generally advised, particularly for those on aromatase inhibitors. Intravaginal dehydroepiandrosterone and oral ospemiphene have been approved to treat dyspareunia, but safety after breast cancer has not been established. Vaginal laser therapy is being used for VVA but efficacy from sham-controlled studies is lacking. Therapies undergoing development include lasofoxifene, neurokinin B inhibitors, stellate ganglion blockade, vaginal testosterone, and estetrol. Conclusions: Nonhormone options and therapies are available for treatment of estrogen depletion symptoms and clinical problems after a diagnosis of breast cancer. Individualization of treatment is essential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884 · cited 18×
“In general, the use of low-dose vaginal estrogen in breast cancer survivors has been discouraged, particularly in those receiving AIs (13, 68).”
BackgroundInfluentialSelf-citationHoward-Anderson, J., Ganz, P. A., Bower, J. E., & Stanton, A. L. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr541 · Cited by 830 · cited 1×
“chemotherapeutic agents on the ovary (7).”
Rocca, W. A., Bower, J. H., Maraganore, D. M., Ahlskog, J. E., Grossardt, B. R., de Andrade, M., & Melton, L. J. (2007) · Neurology · doi:10.1212/01.wnl.0000276984.19542.e6 · Cited by 827
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Avenell, A., Gillespie, W. J., Gillespie, L. D., & O'Connell, D. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000227.pub3 · Cited by 667
Endocrine treatment of breast cancer in women
SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-221 · Cited by 399
Self-citationRelationship of Sedentary Behavior and Physical Activity to Incident Cardiovascular Disease
Chomistek, A. K., Manson, J. E., Stefanick, M. L., Lu, B., Sands-Lincoln, M., Going, S. B., Garcia, L., Allison, M. A., Sims, S. T., LaMonte, M. J., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.031 · Cited by 389 · cited 1×
“Specifically, physical activity improves postmenopausal women’s balance, body composition, muscle strength, and bone health; improves mood (45); reduces cardiovascular risk (46, 47); and, potentially, reduces falls contributing to osteoporotic fractures (47).”
BackgroundRance, N. E., Dacks, P. A., Mittelman-Smith, M. A., Romanovsky, A. A., & Krajewski-Hall, S. J. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.003 · Cited by 380 · cited 1×
“Miscellaneous agents Recent data suggest that the kisspeptin, neurokinin B, and dynorphin neurons in the arcuate nucleus of the hypothalamus—particularly, neurokinin B—mediate hot flashes (149).”
Background
Cited by
Hormone therapy for postmenopausal women
Pinkerton, J. V. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp1714787 · Cited by 220
Self-citationLong-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?
Tommasi, C., Balsano, R., Corianò, M., Pellegrino, B., Saba, G., Bardanzellu, F., Denaro, N., Ramundo, M., Toma, I., Fusaro, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237239 · Cited by 76
Shan, D., Zou, L., Liu, X., Shen, Y., Cai, Y., & Zhang, J. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.12.011 · Cited by 55
Metadata
- Authors
- Santen, R. J., Stuenkel, C. A., Davis, S. R., Pinkerton, J. V., Gompel, A., & Lumsden, M. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2017-08-02
- Volume
- 102
- Issue
- 10
- Pages
- 3647-3661
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2741387126
- Cited by
- 125
- References
- 19
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.